Related Experiment Video

Updated: Jul 11, 2026

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

Chemoconvulsant-induced seizure susceptibility: toward a common genetic basis?

Yohan Chaix1, Thomas N Ferraro, Eve Lapouble

  • 1Laboratoire de Neurobiologie, Equipe Génétique des Epilepsies, Université d'Orléans, France.

Epilepsia
|October 4, 2007
PubMed

Insights

Researchers investigated the genetic basis of epilepsy using mouse models. They identified two quantitative trait loci (QTLs) on Chromosome 1 associated with seizure susceptibility, highlighting this region's importance in epilepsy research.

Area of Science:

  • Neurogenetics
  • Epilepsy Research
  • Mouse Models

Background:

  • Understanding the genetic architecture of epilepsy is challenging.
  • Mouse models are crucial for genetic studies due to fewer restrictions compared to humans.
  • Pharmacogenetic approaches using compounds like kainic acid and ss-carbolines are key for epilepsy research.

Purpose of the Study:

  • To investigate the genetic factors contributing to seizure susceptibility.
  • To explore the significance of a specific chromosomal region in epilepsy.
  • To build upon previous quantitative trait loci (QTL) mapping studies.

Main Methods:

  • Utilized a mouse model for studying convulsive epilepsies.
  • Employed a pharmacogenetic approach with methyl 6, 7-dimethoxy-4-ethyl-ss-carboline-3-carboxylate (DMCM).
  • Mapped quantitative trait loci (QTLs) for seizure response using a segregating F2 population.

Main Results:

  • Identified two QTLs associated with DMCM-induced seizure response.
  • One QTL was localized to the distal part of Chromosome 1.
  • This chromosomal region has been implicated in other seizure susceptibility studies.

Conclusions:

  • The distal region of Chromosome 1 plays a significant role in influencing seizure susceptibility.
  • Further research into this chromosomal fragment is warranted to understand its role in epilepsy.
  • This study contributes to the ongoing effort to unravel the genetic basis of epilepsy.

More Related Videos

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy06:58

A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy

Published on: July 12, 2021

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...